NSI-189

This note is educational and is not personal medical advice. Effects vary by baseline status, dose, product quality, medications, sleep debt, diet, and health conditions.

Summary / What it does

NSI-189 is an investigational compound originally developed around hippocampal neurogenesis and depression research. It is not an approved supplement or medication for general cognitive enhancement.

Useful cross-links: Neurotrophic & Growth Factors, Neurotransmitter Balance. Its effects are best evaluated through the Long Term & Permanent Effects pattern rather than as a single isolated effect.

How it works in the brain (detailed scientific mechanisms)

NSI-189 was discovered through screening for compounds that increased hippocampal neural stem cell activity, so its mechanism is less receptor-defined than many nootropics. Preclinical data connect it with hippocampal neurogenesis, increased MAP2-positive neuronal structure, synaptic remodeling, and behavioral recovery in stress or injury models. It is often described as a hippocampal neurogenic compound rather than a classical monoamine antidepressant.

The exact upstream target remains uncertain, but downstream effects appear to involve neurogenic and plasticity-related transcription programs, potentially including BDNF-linked remodeling, dendritic growth, and hippocampal circuit integration. This explains the delayed onset and mood-memory profile: the proposed effect is structural and neuroplastic, not acute transmitter release.

Related mechanism notes: Neurotrophic & Growth Factors, Neurotransmitter Balance.

Different variations/forms

NSI-189 phosphate and free base are discussed in research-chemical contexts. These forms differ in weight and handling, adding confusion for nonmedical users.

Time to action / onset

Mood or cognitive effects would be expected over weeks, not as an acute focus agent.

Half-life

Public practical pharmacokinetic guidance is insufficient for casual use.

Dosage

No approved nootropic dosing exists. This wiki does not provide a self-experimentation protocol.

Positive effects

Potential positives include mood support, cognitive flexibility, and hippocampal plasticity, but evidence remains limited.

Reported Effects

People who report benefits from NSI-189 often describe mood lift, emotional color returning, improved verbal flow, or a sense of hippocampal “space” and cognitive flexibility over weeks. Negative reports include anxiety, headaches, insomnia, emotional instability, or feeling weirdly disconnected. It is often discussed as slow and mood-active rather than an acute focus aid.

Side effects / contraindications

Side effects can include anxiety, emotional changes, insomnia, headache, GI effects, and possible mania risk in susceptible individuals.

Where it is found in food or nature (natural sources)

NSI-189 is synthetic and not found in food.

Protocol

No approved dosing protocol exists. Phase II trials used 40–80 mg/day of NSI-189 phosphate. Because of mood-system unpredictability (mania risk, anxiety, emotional instability), this wiki does not provide a self-directed protocol. Not appropriate alongside psychiatric medications without medical supervision.

Key Research

• Johe et al. (2013): Phase I trial of NSI-189 phosphate demonstrated acceptable safety and preliminary signals of cognitive improvement in healthy subjects.
• Fava et al. (2016): NSI-189 phosphate showed significant improvements in depressive symptoms and cognitive function in a Phase II RCT for major depressive disorder.
• Neuralstem preclinical literature: NSI-189 consistently increased hippocampal neural progenitor proliferation and BDNF expression in rodent stress models — mechanistic support.

Forms & Sourcing

Research-chemical suppliers sell NSI-189 phosphate or free base, but quality varies. No pharmaceutical product is OTC-available. Phase II data was from pharmaceutical-grade formulations that community products cannot replicate. Third-party testing required.

Other notes

NSI-189 belongs near Dihexa and Cerebrolysin as a neuroplasticity research note, but its evidence and safety status are not equivalent to approved therapies.

Related notes: Dihexa, Cerebrolysin, Lions Mane, Bacopa Monnieri